FFA
MLYS icon

Farther Finance Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Farther Finance Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$808 Sell
30
-7
-19% -$192 ﹤0.01% 5423
2026
Q1 		$977 Buy
37
+2
+6% +$59 ﹤0.01% 5116
2025
Q4 		$1.27K Buy
35
+2
+6% +$80 ﹤0.01% 4849
2025
Q3 		$1.25K Buy
33
+16
+94% +$346 ﹤0.01% 4304
2025
Q2 		$230 Hold
17
– – ﹤0.01% 4184
2025
Q1 		$235 Hold
17
– – ﹤0.01% 3920
2024
Q4 		$209 Hold
17
– – ﹤0.01% 3650
2024
Q3 		$206 Hold
17
– – ﹤0.01% 3644
2024
Q2 		$207 Hold
17
– – ﹤0.01% 3489
2024
Q1 		$222 Hold
17
– – ﹤0.01% 3244
2023
Q4 		$146 Buy
+17
New +$133 ﹤0.01% 3265

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Farther Finance Advisors's MLYS Position: Q2 2026 in Review

Farther Finance Advisors reduced its Mineralys Therapeutics (MLYS) stake by 19% in Q2 2026, selling an estimated $192 and leaving 30 shares worth $808. The position accounts for ﹤0.01% of the portfolio, ranked #5423.

Farther Finance Advisors first reported a position in MLYS in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.27K in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Farther Finance Advisors held 30 shares of Mineralys Therapeutics worth $808 as of Q2 2026.
  • Farther Finance Advisors sold 7 Mineralys Therapeutics shares in Q2 2026, an estimated $192.
  • Mineralys Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5423 holding.
  • Farther Finance Advisors first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Farther Finance Advisors's Mineralys Therapeutics position peaked at $1.27K in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.